Equities analysts expect that Acadia Healthcare (NASDAQ:ACHC) will announce earnings per share (EPS) of $0.47 for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Acadia Healthcare’s earnings, with estimates ranging from $0.47 to $0.48. Acadia Healthcare posted earnings of $0.46 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.2%. The firm is expected to report its next earnings report after the market closes on Tuesday, May 1st.
According to Zacks, analysts expect that Acadia Healthcare will report full year earnings of $2.46 per share for the current fiscal year, with EPS estimates ranging from $2.42 to $2.50. For the next year, analysts anticipate that the firm will post earnings of $2.77 per share, with EPS estimates ranging from $2.63 to $2.92. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Acadia Healthcare.
Acadia Healthcare (NASDAQ:ACHC) last posted its earnings results on Wednesday, February 21st. The company reported $0.61 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.07. The company had revenue of $724.50 million for the quarter, compared to analyst estimates of $713.20 million. Acadia Healthcare had a net margin of 6.92% and a return on equity of 8.16%. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period last year, the business posted $0.59 earnings per share.
Several research firms have weighed in on ACHC. BidaskClub lowered shares of Acadia Healthcare from a “strong-buy” rating to a “buy” rating in a report on Tuesday. ValuEngine lowered shares of Acadia Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, April 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $45.00 target price (up from $40.00) on shares of Acadia Healthcare in a report on Friday, February 23rd. Wells Fargo began coverage on shares of Acadia Healthcare in a report on Tuesday, January 30th. They issued an “outperform” rating and a $41.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a report on Monday, February 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $44.50.
ACHC opened at $38.80 on Friday. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $3,425.00, a price-to-earnings ratio of 16.80, a PEG ratio of 1.27 and a beta of 0.63. Acadia Healthcare has a twelve month low of $26.92 and a twelve month high of $54.34.
In related news, Director Reeve B. Waud sold 7,698 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $42.03, for a total transaction of $323,546.94. Following the sale, the director now directly owns 10,088 shares in the company, valued at $423,998.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Randall P. Goldberg sold 960 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $38.47, for a total transaction of $36,931.20. Following the sale, the vice president now owns 6,942 shares in the company, valued at $267,058.74. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 401,360 shares of company stock worth $15,759,096. 2.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB bought a new position in Acadia Healthcare in the fourth quarter valued at $231,000. Tuttle Tactical Management LLC bought a new position in Acadia Healthcare in the fourth quarter valued at $725,000. MetLife Investment Advisors LLC bought a new position in Acadia Healthcare in the fourth quarter valued at $1,686,000. Macquarie Group Ltd. grew its position in Acadia Healthcare by 78.8% in the fourth quarter. Macquarie Group Ltd. now owns 37,540 shares of the company’s stock valued at $1,225,000 after purchasing an additional 16,540 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Acadia Healthcare by 727.5% in the fourth quarter. Jane Street Group LLC now owns 54,790 shares of the company’s stock valued at $1,788,000 after purchasing an additional 48,169 shares in the last quarter.
TRADEMARK VIOLATION WARNING: This piece was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/17/acadia-healthcare-achc-expected-to-announce-earnings-of-0-47-per-share.html.
About Acadia Healthcare
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Get a free copy of the Zacks research report on Acadia Healthcare (ACHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.